Results 221 to 230 of about 644,627 (253)

The Sydney Triage to Admission Risk Tool With Artificial Intelligence (START-AI) to Support Decision Making in Emergency Departments: Model Explainability and Feature Importance Analysis. [PDF]

Emerg Med Australas
Dinh M, Corbett E, Ngo TT, Salmon E, Khan SA, Pethani F, Moore N, Koprinska I.   +7 more
europepmc   +1 more source

Mutant p53R273H disrupts PDPK1 homodimerization and contributes to PDPK1 activation

Molecular Oncology, EarlyView.
How mutant p53R273H drives AKT signaling is unclear. We show that p53R273H, but not wild‐type, directly binds PDPK1 via a mutation‐dependent conformational change. This interaction disrupts inhibitory PDPK1 homodimerization and enhances AKT phosphorylation.
Mei Chee Lim, Alvin Kunyao Guo, Yoko Itahana, Srinivasaraghavan Kannan, Valerie Goh, Mingmin Ong, Terina Yan Wen Tay, Weiying Ye, Sabhashina Radha Krishnan, Jun Nishiyama, Chandra S Verma, Koji Itahana   +11 more
wiley   +1 more source

Risk analysis and warning model of post-noncardiac surgery acute kidney injury: A retrospective observational study. [PDF]

Medicine (Baltimore)
Xu Y, Li W, Pang Q, Wu L, Dong X, Fu W, Zhang A.   +6 more
europepmc   +1 more source

Targeting the EpCAM‐AXL axis to overcome drug resistance in lung cancer

Molecular Oncology, EarlyView.
Lung cancer cells often evade therapy by hijacking signaling pathways. We reveal that cleaved EpCAM (sEpCAM) stabilizes the oncogenic protein AXL, driving NF‐κB and STAT3‐mediated chemoresistance. This EpCAM‐AXL axis identifies a high‐risk patient subset with poor prognosis.
Alexa Guerrero‐Alba, Mark Shacker, Timothy P. Fleming, Michael A. Smith, Ross M. Bremner, Narendra V. Sankpal   +5 more
wiley   +1 more source

Interpretable predictive model for deterioration of kidney function in patients with stage 4 cardiovascular-kidney-metabolic syndrome. [PDF]

BMC Nephrol
Wang F, Shang Z, Gao Y, Deng Z, Tang W, Wang Y.   +5 more
europepmc   +1 more source

Characterization of therapeutic antibodies targeting lymphatic and vascular resistance factor for the treatment of hypervascularized and highly metastatic cancers

Molecular Oncology, EarlyView.
LVRF (lymphatic and vascular resistance factor) is a VEGFA splice variant upregulated in response to anti‐angiogenic therapy that fosters tumor adaptation through enhanced vascularization, lymphangiogenesis, and metastatic dissemination. Targeting LVRF with fully human neutralizing antibodies disrupts these processes and limits resistant tumor growth ...
Marion David, Arthur Karaulic, Audrey Bennetot, Clémence Fournier, Quentin Odet, Arthur Gouraud, Isabelle Bourget, Cédric Gaggioli, Sandy Giuliano, Frédéric Luciano, Olivier Léger, Zaki Sellam, Gilles Pagès   +12 more
wiley   +1 more source

ALPS-HCC Score: A Dynamic Liver Stiffness Measurement-Based Machine Learning Model to Predict Risk of Hepatocellular Carcinoma. [PDF]

Liver Int
Huang Y, Yu H, Yang B, Jiang H, Hu C, Yu Q, Xi X, Li M, Lei Y, Wu B, Xie B, Ding H, Yang Y.   +12 more
europepmc   +1 more source

Variance of the root mean square value of the residuals of sine fitting in the presence of additive noise. [PDF]

Sci Rep
Alegria FAC.
europepmc   +1 more source

Development and Validation of an Early Severity Prediction Model for Hypertriglyceridemia-Associated Acute Pancreatitis: A Multicenter Cohort Study. [PDF]

J Inflamm Res
Yao W, Zhao C, Cao L, Yang H, Liu Y, Li S, Wang L, Zhou J, Wang Z, Ke L, Bu Y, Chinese Acute Pancreatitis Clinical Trials Group (CAPCTG), Chinese Acute Pancreatitis Clinical Trials Group (CAPCTG) includes the following participants (in alphabetical order): .   +12 more
europepmc   +1 more source

Measurement Error Models Enable Accurate Correlation of Nanoscale Properties and Structures. [PDF]

ACS Nano
Pintar AL, Madison AC, Copeland CR, Farkas N, Stavis SM.   +4 more
europepmc   +1 more source